The Measurement of Donor-Specific Cell-Free DNA Identifies Recipients With Biopsy-Proven Acute Rejection Requiring Treatment After Liver Transplantation.
Journal
Transplantation direct
ISSN: 2373-8731
Titre abrégé: Transplant Direct
Pays: United States
ID NLM: 101651609
Informations de publication
Date de publication:
Jul 2019
Jul 2019
Historique:
received:
23
11
2018
revised:
15
03
2019
accepted:
28
03
2019
entrez:
24
7
2019
pubmed:
25
7
2019
medline:
25
7
2019
Statut:
epublish
Résumé
Assessment of donor-specific cell-free DNA (dscfDNA) in the recipient is emerging as a noninvasive biomarker of organ rejection after transplantation. We previously developed a digital polymerase chain reaction (PCR)-based approach that readily measures dscfDNA within clinically relevant turnaround times. Using this approach, we characterized the dynamics and evaluated the clinical utility of dscfDNA after liver transplantation (LT). Deletion/insertion polymorphisms were used to distinguish donor-specific DNA from recipient-specific DNA. Posttransplant dscfDNA was measured in the plasma of the recipients. In the longitudinal cohort, dscfDNA was serially measured at days 3, 7, 14, 28, and 42 in 20 recipients. In the cross-sectional cohort, dscfDNA was measured in 4 clinically stable recipients (>1-y posttransplant) and 16 recipients (>1-mo posttransplant) who were undergoing liver biopsies. Recipients who underwent LT without complications demonstrated an exponential decline in dscfDNA. Median levels at days 3, 7, 14, 28, and 42 were 1936, 1015, 247, 90, and 66 copies/mL, respectively. dscfDNA was higher in recipients with treated biopsy-proven acute rejection (tBPAR) when compared to those without. The area under the receiver operator characteristic curve of dscfDNA was higher than that of routine liver function tests for tBPAR (dscfDNA: 98.8% with 95% confidence interval, 95.8%-100%; alanine aminotransferase: 85.7%; alkaline phosphatase: 66.4%; gamma-glutamyl transferase: 80.1%; and bilirubin: 35.4%). dscfDNA as measured by probe-free droplet digital PCR methodology was reflective of organ health after LT. Our findings demonstrate the potential utility of dscfDNA as a diagnostic tool of tBPAR.
Sections du résumé
BACKGROUND
BACKGROUND
Assessment of donor-specific cell-free DNA (dscfDNA) in the recipient is emerging as a noninvasive biomarker of organ rejection after transplantation. We previously developed a digital polymerase chain reaction (PCR)-based approach that readily measures dscfDNA within clinically relevant turnaround times. Using this approach, we characterized the dynamics and evaluated the clinical utility of dscfDNA after liver transplantation (LT).
METHODS
METHODS
Deletion/insertion polymorphisms were used to distinguish donor-specific DNA from recipient-specific DNA. Posttransplant dscfDNA was measured in the plasma of the recipients. In the longitudinal cohort, dscfDNA was serially measured at days 3, 7, 14, 28, and 42 in 20 recipients. In the cross-sectional cohort, dscfDNA was measured in 4 clinically stable recipients (>1-y posttransplant) and 16 recipients (>1-mo posttransplant) who were undergoing liver biopsies.
RESULTS
RESULTS
Recipients who underwent LT without complications demonstrated an exponential decline in dscfDNA. Median levels at days 3, 7, 14, 28, and 42 were 1936, 1015, 247, 90, and 66 copies/mL, respectively. dscfDNA was higher in recipients with treated biopsy-proven acute rejection (tBPAR) when compared to those without. The area under the receiver operator characteristic curve of dscfDNA was higher than that of routine liver function tests for tBPAR (dscfDNA: 98.8% with 95% confidence interval, 95.8%-100%; alanine aminotransferase: 85.7%; alkaline phosphatase: 66.4%; gamma-glutamyl transferase: 80.1%; and bilirubin: 35.4%).
CONCLUSIONS
CONCLUSIONS
dscfDNA as measured by probe-free droplet digital PCR methodology was reflective of organ health after LT. Our findings demonstrate the potential utility of dscfDNA as a diagnostic tool of tBPAR.
Identifiants
pubmed: 31334336
doi: 10.1097/TXD.0000000000000902
pmc: PMC6616138
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e462Déclaration de conflit d'intérêts
S.K.G., A.D., and H.D. are co-inventors of the patent application PCT/AU2017/050657 (pending). This patent application describes the methodology that was utilized in this study to quantify donor-specific cell-free DNA. The other authors declare no conflicts of interests.
Références
Proc Natl Acad Sci U S A. 2015 Oct 27;112(43):13336-41
pubmed: 26460048
Liver Transpl. 2017 Apr;23(4):487-497
pubmed: 28133934
Hum Immunol. 2017 Apr;78(4):342-349
pubmed: 28267558
Clin Biochem. 2013 Aug;46(12):1099-1104
pubmed: 23643886
Clin Biochem. 2016 Dec;49(18):1354-1360
pubmed: 27129799
Liver Transpl. 2002 Dec;8(12):1147-53
pubmed: 12474154
Sci Transl Med. 2014 Jun 18;6(241):241ra77
pubmed: 24944192
J Am Soc Nephrol. 2017 Jul;28(7):2221-2232
pubmed: 28280140
Proc Natl Acad Sci U S A. 2011 Apr 12;108(15):6229-34
pubmed: 21444804
J Am Coll Cardiol. 2014 Apr 1;63(12):1224-1226
pubmed: 24140666
J Mol Diagn. 2016 Nov;18(6):890-902
pubmed: 27727019
Gut. 1999 Oct;45 Suppl 4:IV1-IV11
pubmed: 10485854
Transpl Int. 2012 May;25(5):555-63
pubmed: 22420754
Am J Transplant. 2015 Oct;15(10):2541-51
pubmed: 26184824
Exerc Immunol Rev. 2015;21:164-73
pubmed: 25826002
Clin Chem. 1997 Aug;43(8 Pt 2):1546-54
pubmed: 9265907
Ann Surg. 2013 Sep;258(3):409-21
pubmed: 24022434
Am J Transplant. 2012 Nov;12(11):3008-20
pubmed: 22882750
Clin Chem. 2017 Mar;63(3):742-750
pubmed: 28100495
J Appl Lab Med. 2017 Nov 1;2(3):309-321
pubmed: 33636851
Clin Chem. 2018 Apr;64(4):749-751
pubmed: 29440117
Nature. 2012 Nov 1;491(7422):56-65
pubmed: 23128226
Clin Chem. 2016 Jul;62(7):1012-9
pubmed: 27354569
Am J Hum Genet. 2002 Oct;71(4):854-62
pubmed: 12205564
PLoS One. 2014 Dec 09;9(12):e113987
pubmed: 25489845
Clin Chem. 2014 Aug;60(8):1105-14
pubmed: 24899692
Am J Transplant. 2013 Jul;13(7):1734-45
pubmed: 23714399
World J Gastroenterol. 2014 May 28;20(20):6180-200
pubmed: 24876739
Am J Gastroenterol. 2002 Oct;97(10):2614-8
pubmed: 12385448
Hepatol Res. 2013 Feb;43(2):165-78
pubmed: 23186289
J Heart Lung Transplant. 2018 Jul;37(7):925-932
pubmed: 29500138
World J Transplant. 2014 Mar 24;4(1):30-9
pubmed: 24669365
Transplantation. 2013 Jul 15;96(1):97-101
pubmed: 23756769
Clin Chem. 2009 Nov;55(11):1958-66
pubmed: 19729469
Nat Methods. 2013 Oct;10(10):1003-5
pubmed: 23995387
Clin Chem Lab Med. 2016 Jul 1;54(7):1147-55
pubmed: 26574891
Transplant Proc. 2015 Oct;47(8):2400-3
pubmed: 26518940
Lancet. 1998 May 2;351(9112):1329-30
pubmed: 9643800
Clin Chem. 2013 Dec;59(12):1732-41
pubmed: 24061615
Clin Gastroenterol Hepatol. 2017 Apr;15(4):584-593.e2
pubmed: 27567694
PLoS Med. 2017 Apr 25;14(4):e1002286
pubmed: 28441386
Front Cardiovasc Med. 2016 Sep 22;3:33
pubmed: 27713880
Transplantation. 2014 Sep 15;98(5):e43-5
pubmed: 25171533
Genomics Inform. 2017 Mar;15(1):2-10
pubmed: 28416944